Dr Berrie brings over 20 years of scientific, business and financial experience in the biotechnology and healthcare industries. He is Director of Tech Investor Ltd which consults and advises government organisations, regions and companies throughout the biotech sector on the commercialisation of science, including business development and capital raising. He has served as Co-Founder/Chairman of TTS Global Initiative which globally facilitates deal flow in the early stage/SME biotech sector and was a partner of several EU Horizon 2020 multimillion Euro projects aiding the European SME sector.
Prior, Dr Berrie was the Chief Executive Officer and Editor-in-Chief of the Biotechnology Investment Today Group where he worked with numerous prestigious clients from both the healthcare and the financial services industries, including the US National Institutes of Health (NIH), Pfizer, GSK, Needham & Co, Orbimed, TVM, JPMorgan and many more. Previously, he was Head of Global Intelligence and Business Development for the Nature Publishing Group and before that he was the Director, Compound Registry, Patent Database for the Investigational Drug database (IDdb3) of Current Drugs, now owned by Thomson Reuters.
He has worked at Schering AG, is a Chartered Chemist (CChem) and a Member of the Royal Society of Chemistry (MRSC). He has a Bachelor of Science (Hons) in Chemistry (Applied) from Northumbria University, a PhD in Organic Chemistry from Imperial College, London and a Post- doctoral Fellowship in Organometallic Chemistry from the Universidad de Oviedo.